Shanghai RAAS Blood Products Co., Ltd. Overview
Pro stress-test →Shanghai RAAS Blood Products engages in the manufacture and sale of blood products in China. The company offers human serum albumin, human intravenous immunoglobulin, human coagulation factor VIII, human prothrombin complex, human fibrinogen, human thrombin and human fibrin adhesive, human immunoglobulin, hepatitis B immunoglobulin, tetanus immunoglobulin, and rabies immunoglobulin products. Founded in October 1988 as the first large sino-foreign joint venture in production of blood products.
Strategic Profile
Pro stress-test →RAAS is a blood products manufacturer in China with high comprehensive utilization of plasma raw materials and is engaged in the research, development, and manufacture of blood products and plasma-derived medical products. China accounts for 96.6% of net sales, providing strong domestic market penetration. The company made a merger/acquisition deal with Nanyue Biopharming on March 26, 2025, signaling growth through consolidation.
Competitive Landscape
Pro stress-test →Shanghai RAAS operates in the plasma-derived therapeutics segment dominated by global players like Grifols, CSL Limited, and domestic Chinese competitors. The company maintains a strong domestic competitive advantage through established supply chains and regulatory relationships, but faces increasing competition from both international firms and emerging local manufacturers in the Chinese blood products market.
Industry Context
Shanghai RAAS Blood Products Co., Ltd. operates in Pharmaceuticals - Plasma-Derived Therapeutics & Blood Products.
Key facts
Founded: 1988 · Headquarters: Shanghai, China · Employees: 3350 · Revenue: $1.09B · Market cap: $6.36B